Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00253747 · ClinicalTrials.gov registry record · Phase 3

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

A Phase 3 study of Smoking and ADHD, sponsored by University of Cincinnati.

Completed
Registry status
Phase 3
Development phase
255
Enrollment target
6
Study locations

NCT00253747 is a Phase 3 study of Smoking and ADHD that has completed, run by University of Cincinnati. The registered enrollment target is 255 participants, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (44% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00253747, a Phase 3 study of Smoking and ADHD, has completed, sponsored by University of Cincinnati.

COMPLETED
Registry status
Phase 3
Development phase
255 participants
Enrollment target
6
Study locations

Study Summary

The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with Attention Deficit Hyperactivity Disorder (ADHD).

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Osmotic-Release Methylphenidate

Study Locations (6)

New York

  • VA New York Harbor Healthcare System - New York
  • New York State Psychiatric Institute - Smoking Cessation Program - New York

Massachusetts

  • Massachusetts General Hospital - Cambridge

Minnesota

  • Mayo Clinic Nicotine Research Program - Rochester

Ohio

  • Maryhaven, Inc. - Columbus

Oregon

  • Kaiser Permanente (Center for Health Research) - Portland

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2005-11
Est. Completion 2008-03
Phase Phase 3

Sponsor

University of Cincinnati

245 total trials

What the Registry Record Tells You About NCT00253747

The ClinicalTrials.gov registry entry for NCT00253747 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (44% lower). The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00253747 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, Massachusetts, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00253747 about?

NCT00253747 is a clinical study titled "Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)". The objective of this study is to evaluate whether Osmotic-Release Methylphenidate (OROS MPH), relative to placebo, increases the effectiveness of standard smoking treatment (i.e., nicotine patch and individual smoking cessation counseling) in obtaining prolonged abstinence for smokers with Attentio...

What is the current status of trial NCT00253747?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2005-11. Estimated completion is 2008-03.

What conditions does trial NCT00253747 study?

This clinical trial studies the following conditions: Smoking, ADHD.

What interventions are being tested in trial NCT00253747?

The interventions under investigation include: Placebo (DRUG), Osmotic-Release Methylphenidate (DRUG).

Who is sponsoring clinical trial NCT00253747?

This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00253747 being conducted?

This trial has 6 study locations across Massachusetts, Minnesota, New York, Ohio, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.